ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Vigil Neuroscience Inc

Vigil Neuroscience Inc (VIGL)

2.20
-0.81
(-26.91%)
Closed 27 November 8:00AM
2.24
0.04
(1.82%)
After Hours: 11:35AM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
2.24
Bid
2.20
Offer
2.23
Volume
1,660,801
2.08 Day's Range 3.00
2.1901 52 Week Range 6.06
Market Cap
Previous Close
3.01
Open
3.00
Last Trade
1
@
2.23
Last Trade Time
Financial Volume
US$ 3,777,363
VWAP
2.2744
Average Volume (3m)
88,237
Shares Outstanding
40,879,485
Dividend Yield
-
PE Ratio
-1.08
Earnings Per Share (EPS)
-2.02
Revenue
-
Net Profit
-82.64M

About Vigil Neuroscience Inc

Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple ther... Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Dover, Delaware, USA
Founded
-
Vigil Neuroscience Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker VIGL. The last closing price for Vigil Neuroscience was US$3.01. Over the last year, Vigil Neuroscience shares have traded in a share price range of US$ 2.1901 to US$ 6.06.

Vigil Neuroscience currently has 40,879,485 shares in issue. The market capitalisation of Vigil Neuroscience is US$123.05 million. Vigil Neuroscience has a price to earnings ratio (PE ratio) of -1.08.

VIGL Latest News

Vigil Neuroscience to Present at Upcoming Investor Conferences

WATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the...

Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update

- Final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP planned for first half of 2025 - - Data from Phase 1 clinical trial evaluating VG-3927 in Alzheimer’s Disease on...

Vigil Neuroscience to Present at Guggenheim Healthcare Innovation Conference

WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the...

Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927

WATERTOWN, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.7-23.80952380952.943.262.1901467823.06019816CS
4-1.64-42.26804123713.884.062.1901520653.36644891CS
12-1.24-35.6321839083.484.122.1901882373.53937054CS
26-1.42-38.79781420773.666.062.19013085634.16572329CS
52-0.89-28.43450479233.136.062.19012080583.93865088CS
156-9.76-81.33333333331218.272.181120375.71119057CS
260-9.76-81.33333333331218.272.181120375.71119057CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
PSTXPoseida Therapeutics Inc
US$ 9.38
(227.97%)
29.42M
IMGCIMG Inc
US$ 1.615
(156.35%)
114.46M
IDAIT Stamp Inc
US$ 0.364
(102.22%)
549.04M
PGHLPrimega Group Holdings Ltd
US$ 20.95
(98.77%)
2.77M
TOYOTOYO Company Ltd
US$ 5.41
(86.55%)
48.64M
ALECAlector Inc
US$ 2.575
(-34.97%)
8.13M
ABVEAbove Food Ingredients Inc
US$ 0.5338
(-34.42%)
1.66M
LGCLLucas GC Ltd
US$ 0.7511
(-33.53%)
2.48M
ADDColor Star Technology Company Ltd
US$ 4.19
(-31.87%)
205.78k
LESLLeslies Inc
US$ 2.445
(-30.34%)
24.55M
IDAIT Stamp Inc
US$ 0.364
(102.22%)
549.04M
ELABElevai Labs Inc
US$ 0.01255
(-21.07%)
323.24M
NVDANVIDIA Corporation
US$ 136.92
(0.66%)
186M
RGTIRigetti Computing Inc
US$ 2.195
(-20.18%)
124.14M
IMGCIMG Inc
US$ 1.615
(156.35%)
114.46M

VIGL Discussion

View Posts
Monksdream Monksdream 3 months ago
VIGL under $4
👍️0
Monksdream Monksdream 4 months ago
VIGL under $5
👍️0
Monksdream Monksdream 5 months ago
VIGL under $5
👍️0
MiamiGent MiamiGent 5 months ago
Good insight.
👍️0
Zorro Zorro 5 months ago
More than likely there is an announcement baked into this deal that will allow for the sale of those 7.44 shares at a profit.
👍️ 1
PonkenPlonken PonkenPlonken 5 months ago
Those 3.80 dippers look pretty smart now ;)
👍️ 1
MiamiGent MiamiGent 5 months ago
$VIGL At 12 noon:

Volume
13,927,465
90 Day Avg. Vol.
147,064

9.5 X's 90 DAV
👍️0
MiamiGent MiamiGent 5 months ago
VIGL Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi
GLOBENEWSWIRE
2:00 AM ET Jun-27-2024
- Sanofi to invest $40 million at an as-converted price of $7.44 per share of common stock-

- Sanofi to receive an exclusive right of first negotiation for license of Company’s small molecule TREM2 agonist program, including VG-3927, currently in phase 1 clinical studies -

- Company expects proceeds to extend cash runway into 2026 -

WATERTOWN, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (VIGL.NaE) , a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, is pleased to announce that Sanofi has made a $40 million strategic investment in the Company at an as-converted price of $7.44 per share of common stock. Sanofi will purchase 537,634 of the Company’s Series A non-voting preferred shares, each share of which shall be convertible into ten shares of common stock. The Company will use the proceeds to fund its research and development activities.

“We are excited by this strategic investment from Sanofi, one of the world’s leading biopharmaceutical companies, for our research and development programs,” said Ivana Magovcevic-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil. “We view Sanofi’s investment in Vigil as a validation of our promising precision medicine approach led by our two differentiated TREM2 modalities, iluzanebart and VG-3927, and Sanofi has provided valuable capital to help fund our pipeline. We look forward to the opportunity to work with Sanofi as we continue to advance our small molecule TREM2 agonist program.”

“Recent discoveries have highlighted the role of microglial signaling and neuroinflammation in neurodegenerative diseases. TREM2 is a well credentialed microglia target in this context,” said Erik Wallstroem, Sanofi's Global Head of Neurology Development. “The investment in Vigil strengthens our commitment to immunoscience and neuroimmunology.”

In connection with the equity investment, Vigil has granted Sanofi the exclusive right of first negotiation (ROFN) for an exclusive license, grant or transfer of rights to research, develop, manufacture and commercialize the Company’s small molecule TREM2 agonist program, including its clinical candidate, VG-3927. VG-3927 is currently being evaluated in a phase 1 clinical study for the potential treatment of Alzheimer’s disease.

Based on current projections, the Company expects that the proceeds from Sanofi’s investment will extend its cash runway into 2026.

About Vigil Neuroscience (VIGL.NaE)

Vigil Neuroscience (VIGL.NaE) is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Vigil is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Iluzanebart, Vigil’s lead clinical candidate, is a fully human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 (TREM2) in people with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. Vigil is also developing VG-3927, a novel small molecule TREM2 agonist, to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease (AD) in genetically defined subpopulations.

Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements” of Vigil Neuroscience (VIGL.NaE) (“Vigil” or the “Company”) that are made pursuant to the safe harbor provisions of the federal securities laws.......
👍️0
PonkenPlonken PonkenPlonken 5 months ago
they often do this in bio land on those that open a quarter+ up, reverse to 0 and then let them go the days after
👍️ 1
PonkenPlonken PonkenPlonken 5 months ago
agree looking good down here
👍️0
MiamiGent MiamiGent 5 months ago
VIGL In @ 3.83 for the scalp
👍️0
reena969 reena969 5 months ago
VIGL: My guess is that the $7 price target for VIGL will be set for the 9:30 market opening, allowing the algorithm to gradually move it to that price point. 1498 in free left, I'll check back later.
Happy Trading
👍️0
tw0122 tw0122 5 months ago
VIGL chop zone makes sense just read news $7.44 max pain 4.80- 7.41 chop zone

Vigil Neuroscience, Inc. (VIGL) announces that Sanofi (SNY) has made a $40 million strategic investment in the Company at an as-converted price of $7.44 per share of common stock. Sanofi will purchase 537,634 of the Company's Series A non-voting preferred shares, each share of which shall be convertible into ten shares of common stock. The Company will use the proceeds to fund its research and development activities.In connection with the equity investment, Vigil has granted Sanofi the exclusive right of first negotiation (ROFN) for an exclusive license, grant or transfer of rights to research, develop, manufacture and commercialize the Company's small molecule TREM2 agonist program, including its clinical candidate, VG-3927. VG-3927 is currently being evaluated in a phase 1 clinical study for the potential treatment of Alzheimer's disease.Based on current projections, the Company expects that the proceeds from Sanofi's investment will extend its cash runway into 2026.
👍️0
reena969 reena969 5 months ago
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174665212

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174665196
👍️0
tw0122 tw0122 5 months ago
VIGL 5.50s
👍️0
Monksdream Monksdream 6 months ago
VIGL under $5
👍️0
Monksdream Monksdream 7 months ago
VIGL under $3
👍️0
Terpi Terpi 1 year ago
This one trades this, looks like it may be finding a bottom.
👍️0

Your Recent History

Delayed Upgrade Clock